← All Senti Biosciences, INC filings

Senti Biosciences, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SNTI
Senti Biosciences, INC
10-K/A: Senti Biosciences Files Amended 10-K with Governance Details
Senti Biosciences Holdings, Inc. has filed an amendment to its 2025 annual report, providing detailed information on its directors, executive officers, corporate governance, and executive compensation.
NASDAQ
SNTI
Senti Biosciences, INC
10-K: Senti Biosciences Faces Going Concern Doubt Amidst Clinical Progress
Senti Biosciences reported significant losses and expressed substantial doubt about its ability to continue as a going concern, despite positive Phase 1 clinical data for its lead CAR-NK cell therapy, SENTI-202.
NASDAQ
SNTI
Senti Biosciences, INC
10-K: Senti Biosciences Reports 2024 Financial Results, Highlights Clinical Progress
Senti Biosciences details its financial performance for 2024 and provides updates on its clinical programs, including progress with SENTI-202 and SN301A.
NASDAQ
SNTI
Senti Biosciences, INC
10-K/A: Senti Biosciences Files Amendment No. 1 to 2023 Annual Report on Form 10-K
Senti Biosciences has filed an amendment to its 2023 annual report to include required information regarding directors, executive compensation, and other corporate governance matters.
NASDAQ
SNTI
Senti Biosciences, INC
10-K: Senti Bio Enters Collaboration with Celest Therapeutics for China Clinical Trials
Senti Biosciences partners with Celest Therapeutics to advance clinical development of SENTI-301A in China, with first patient enrollment expected in the first half of 2024.